Closing The Books On Taxol: GAO Report Fuels Sen. Wyden’s Pricing Push

NIH should consider the cost of new therapies to Medicare when negotiating technology transfers for taxpayer-funded research, Sen. Ron Wyden (D-Ore.) maintained in response to a June 4 1GAO report on the National Institutes of Health's collaboration with Bristol for the oncologic agent Taxol